

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
21 August 2003 (21.08.2003)

PCT

(10) International Publication Number
WO 2003/068943 A3

(51) International Patent Classification⁷: C12N 15/00

(21) International Application Number:
PCT/US2003/004712

(22) International Filing Date: 13 February 2003 (13.02.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/357,002 13 February 2002 (13.02.2002) US
60/362,439 6 March 2002 (06.03.2002) US
60/366,041 19 March 2002 (19.03.2002) US

(71) Applicant (for all designated States except US): INCYTE CORPORATION [US/US]; 3160 Porter Drive, Palo Alto, CA 94304 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): LEHR-MASON, Patricia, M. [US/US]; 360 Clarke Lane, Morgan Hill, CA 95014 (US). KABLE, Amy, E. [US/US]; 2345 Polk Street #4, San Francisco, CA 94109 (US). ELLIOTT, Vicki, S. [US/US]; 3770 Polton Place Way, San Jose, CA 95121 (US). MARQUIS, Joseph, P. [US/US]; 4428 Lazy Lane, San Jose, CA 95135 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). CHAWLA, Narinder, K. [US/US]; 33 Union Square, #712, Union City, CA 94587 (US). TRAN, Uyen, K. [US/US]; 2638 Mabury Square, San Jose, CA 95133 (US). JIN, Pei [US/US]; 320 Curtner Avenue #D, Palo Alto, CA 94306 (US). TANG, Y., Tom [US/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). ZEBARJADIAN, Yeganeh [IR/US]; 830 Junipero Serra Boulevard, San Francisco, CA 94127 (US). SWARNAKAR, Anita [CA/US]; 8 Locksley Avenue #5D, San Francisco, CA 94122 (US). HAFALIA, April, J, A. [US/US]; 2227 Calle de Primavera, Santa Clara, CA 95054 (US). COCKS, Benjamin, G. [AU/US]; 1215 Van Dyke Drive, Sunnyvale, CA 94087 (US). WARREN, Bridget, A. [US/US]; 1810 S. El Camino Real #B103, Encinitas, CA 94024 (US). EMERLING, Brooke, M. [US/US]; 833 W. Buena Avenue #2108, Chicago, IL 60613 (US). PEARSON, Cecilia, I. [US/US]; 1019 Forest Court, Palo Alto, CA 94301 (US). CHIEN, David [US/US]; 444 Yerba Buena Avenue, Los Altos, CA 94022 (US). PETERSON, David, P. [US/US]; 970 Cherry Avenue, San Jose, CA 95126

(US). FU, Glenn, K. [US/US]; 4215 Roscommon Way, Dublin, CA 94568 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). JACKSON, Alan, A. [US/US]; 1541 Elwood Drive, Los Gatos, CA 95032 (US). JIANG, Xin [US/US]; 14371 Elva Avenue, Saratoga, CA 95070 (US). HAWKINS, Phillip, R. [US/US]; 750 North Shoreline Boulevard #115, Mountain View, CA 94043 (US). LAL, Preeti, G. [US/US]; P.O. Box 5142, Santa Clara, CA 95056 (US). KHARE, Reena [US/US]; 12650 Orella Court, Saratoga, CA 95070 (US). LEE, Sally [US/US]; 3643 26th Street, San Francisco, CA 94110 (US). LEE, Soo, Yeun [KR/US]; 40 Westdale Avenue, Daly City, CA 94015 (US). RICHARDSON, Thomas, W. [US/US]; 616 Canyon Road #107, Redwood City, CA 94062 (US). CHANG, Hsin-Ru [US/US]; 326 Treasure Island Drive, Belmont, CA 94002 (US).

(74) Agent: FOLEY & LARDNER LLP; Washington Harbour, 3000 K Street, N.W., Suite 500, Washington, D.C. 20007-5143 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
10 February 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SECRETED PROTEINS

(57) Abstract: Various embodiments of the invention provide human secreted proteins (SECP) and polynucleotides which identify and encode SECP. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of SECP.

WO 2003/068943 A3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/04712

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12N 15/00
 US CL : 530/350

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 U.S. : 530/350

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 SID 1: SEQUENCE DATA BASES;GeneSeq, Issued Patents, Published Applications, PIR, UniPro, GenEMBL.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database GenEMBL, AN:AAA75121, TANG et al, 'Gene Sequence', 08 September 2000.	1 and 17

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	
<p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>

Date of the actual completion of the international search

10 November 2004 (10.11.2004)

Date of mailing of the international search report

14 DEC 2004

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, Virginia 22313-1450

Facsimile No. (703) 305-3230

Authorized officer

Sheridan Swope *J. Roberts for*
 Telephone No. (571)-272-1600

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/04712

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claim Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
Please See Continuation Sheet

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1,2,17,18 and 56-106

- Remark on Protest
- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

Group I, claims 1, 2, 17, 18, and 56-106, drawn to polypeptides.

Group II, claims 8, in part, and 3-7, 9, 10, 12, 13, 46, 48-55, and 107-157 drawn to nucleic acid molecules and host cells.

Group III, claims 8, in part, drawn to transgenic organisms.

Group IV, claims 11, 31, 32, 34, 37, 38, and 40-43, drawn to antibodies.

Group V, claims 28, in part, and 14 and 15, drawn to methods for detecting nucleic acid molecules by hybridization.

Group VI, claims 28, in part, and 16, drawn to methods for detecting nucleic acid molecules by amplification.

Group VII, claim 19, drawn to methods of treatment using a polypeptide.

Group VIII, claims 20, 23, and 27, drawn to methods for screening for modulators.

Group IX, claim 21, drawn to an agonist.

Group X, claim 22, drawn to methods of treatment using an agonist.

Group XI, claim 24, drawn to an antagonist.

Group XII, claim 25, drawn to methods of treatment using an antagonist.

Group XIII, claim 26, drawn to drawn to methods for screening for binding agents.

Group XIV, claim 29, drawn to methods for assessing toxicity.

Group XV, claim 30, drawn to in vitro methods of diagnosis using an antibody.

Group XVI, claims 33 and 35, drawn to in vivo methods of diagnosis using an antibody.

Group XVII, claim 36, drawn to methods for making a polyclonal antibody.

Group XVIII, claim 39, drawn to methods for making a monoclonal antibody.

Group XIX, claim 44, drawn to methods of detecting a polypeptide using an antibody.

Group XX, claim 45, drawn to methods of purifying a polypeptide using an antibody.

Group XXI, claim 47, drawn to methods of generating an expression profile.

For each of inventions I-XXI above, restriction to one of the following is also required. Therefore, election is required of one of inventions I-XXI and one of inventions (A)-(JJ).

- (A). SEQ ID No: 52 or a sequence encoding SEQ ID No: 1
- (B). SEQ ID No: 53 or a sequence encoding SEQ ID No: 2.
- (C). SEQ ID No: 54 or a sequence encoding SEQ ID No: 3.
- (D). SEQ ID No: 55 or a sequence encoding SEQ ID No: 4.
- (E). SEQ ID No: 56 or a sequence encoding SEQ ID No: 5.
- (F). SEQ ID No: 57 or a sequence encoding SEQ ID No: 6.
- (G). SEQ ID No: 58 or a sequence encoding SEQ ID No: 7.
- (H). SEQ ID No: 59 or a sequence encoding SEQ ID No: 8.
- (I). SEQ ID No: 60 or a sequence encoding SEQ ID No: 9.
- (J). SEQ ID No: 61 or a sequence encoding SEQ ID No: 10.
- (K). SEQ ID No: 62 or a sequence encoding SEQ ID No: 11.
- (L). SEQ ID No: 63 or a sequence encoding SEQ ID No: 12.
- (M). SEQ ID No: 64 or a sequence encoding SEQ ID No: 13.
- (N). SEQ ID No: 65 or a sequence encoding SEQ ID No: 14.
- (O). SEQ ID No: 66 or a sequence encoding SEQ ID No: 15.
- (P). SEQ ID No: 67 or a sequence encoding SEQ ID No: 16.
- (Q). SEQ ID No: 68 or a sequence encoding SEQ ID No: 17.
- (R). SEQ ID No: 69 or a sequence encoding SEQ ID No: 18.
- (S). SEQ ID No: 70 or a sequence encoding SEQ ID No: 19.
- (T). SEQ ID No: 71 or a sequence encoding SEQ ID No: 20.
- (U). SEQ ID No: 72 or a sequence encoding SEQ ID No: 21.
- (V). SEQ ID No: 73 or a sequence encoding SEQ ID No: 22.
- (W). SEQ ID No: 74 or a sequence encoding SEQ ID No: 23.
- (X). SEQ ID No: 75 or a sequence encoding SEQ ID No: 24.
- (Y). SEQ ID No: 76 or a sequence encoding SEQ ID No: 25.
- (Z). SEQ ID No: 77 or a sequence encoding SEQ ID No: 26.
- (AA). SEQ ID No: 78 or a sequence encoding SEQ ID No: 27.
- (BB). SEQ ID No: 79 or a sequence encoding SEQ ID No: 28.

INTERNATIONAL SEARCH REPORT

- (CC). SEQ ID No: 80 or a sequence encoding SEQ ID No: 29.
- (DD). SEQ ID No: 81 or a sequence encoding SEQ ID No: 30.
- (EE). SEQ ID No: 82 or a sequence encoding SEQ ID No: 31.
- (FF). SEQ ID No: 83 or a sequence encoding SEQ ID No: 32.
- (GG). SEQ ID No: 84 or a sequence encoding SEQ ID No: 33.
- (HH). SEQ ID No: 85 or a sequence encoding SEQ ID No: 34.
- (II). SEQ ID No: 86 or a sequence encoding SEQ ID No: 35.
- (JJ). SEQ ID No: 87 or a sequence encoding SEQ ID No: 36.
- (KK). SEQ ID No: 88 or a sequence encoding SEQ ID No: 37.
- (LL). SEQ ID No: 89 or a sequence encoding SEQ ID No: 38.
- (MM). SEQ ID No: 90 or a sequence encoding SEQ ID No: 39.
- (NN). SEQ ID No: 91 or a sequence encoding SEQ ID No: 40.
- (OO). SEQ ID No: 92 or a sequence encoding SEQ ID No: 41.
- (PP). SEQ ID No: 93 or a sequence encoding SEQ ID No: 42.
- (QQ). SEQ ID No: 94 or a sequence encoding SEQ ID No: 43.
- (RR). SEQ ID No: 95 or a sequence encoding SEQ ID No: 44.
- (SS). SEQ ID No: 96 or a sequence encoding SEQ ID No: 45.
- (TT). SEQ ID No: 97 or a sequence encoding SEQ ID No: 46.
- (UU). SEQ ID No: 98 or a sequence encoding SEQ ID No: 47.
- (VV). SEQ ID No: 99 or a sequence encoding SEQ ID No: 48.
- (WW). SEQ ID No: 100 or a sequence encoding SEQ ID No: 49.
- (XX). SEQ ID No: 101 or a sequence encoding SEQ ID No: 50.
- (YY). SEQ ID No: 102 or a sequence encoding SEQ ID No: 51.

The inventions listed as Groups I-XXI and (A)-(YY) do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical feature for the following reasons: The technical feature linking Groups I-XXI and (A)-(YY) appears to be that they all relate to protein modification and maintenance molecules, for example, proteases. However, protein modification and maintenance molecules, including proteases, are well known in the art (Massova et al, 1998). Therefore, Groups I-XXI and (A)-(YY) share no special technical feature as defined by PCT Rule 13.2, as it does not define a contribution over the prior art. Furthermore, the products of Groups I-IV, IX, XI, and (A)-(YY) do not share a special common structural or functional feature while, the methods of Groups V-VIII, X, and XII-XXI do not use the same reagents or produce the same results. In addition, the methods of Groups V-VIII, X, and XII-XXI do not comprise all of the methods for making or using the products of Groups I-IV, IX, XI, and (A)-(YY). Accordingly, Groups I-XXI and (A)-(YY) are not so linked by the same or a corresponding special technical feature as to form a single general inventive concept.